2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1701

Long Term Outcome of Total Hip Replacement in Patients with Ankylosing Spondylitis
Abstract Number: 2840

Long-Term (104 Week) Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials
Abstract Number: 2843

Long-Term (156-Week) Efficacy and Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from a Phase III, Randomized, Controlled Trial and Open-Label Extension (PALACE 1)
Abstract Number: 619

Long-Term Adverse Events after Daily Concomitant Treatment with 10mg Prednisone in the 2-Year Computer Assisted Management in Early Rheumatoid Arthritis Trial-II
Abstract Number: 1446

Long-Term Effectiveness and Safety of Abatacept in Juvenile Idiopathic Arthritis: Interim Results from the Abatacept in JIA Registry
Abstract Number: 2885

Long-Term Effects of Etanercept on Patient-Reported Outcomes in Early Non-Radiographic Axial Spondyloarthritis: 104-Week Results of a Phase III Study
Abstract Number: 939

Long-Term Efficacy and Safety of Canakinumab in Active Hyperimmunoglobulinemia D with Periodic Fever Syndrome
Abstract Number: 938

Long-Term Efficacy and Safety of Canakinumab in Patients with Active Recurrent or Chronic TNF Receptor-Associated Periodic Syndrome
Abstract Number: 2427

Long-Term Efficacy and Safety of Mycophenolate Mofetil in Childhood Primary Central Nervous System Vasculitis
Abstract Number: 1351

Long-Term Efficacy of Latent Tuberculosis Infection Screening in Juvenile Idiopathic Arthritis Patients Prior to Anti-TNF Treatment in an Endemic Area
Abstract Number: 596

Long-Term High Remission Rates and Distinct Trajectories of Disease Activity Following the Implementation of Treat-to-Target in Early Rheumatoid Arthritis
Abstract Number: 2835

Long-Term Improvements with Certolizumab Pegol in Joints and Extra-Articular Manifestations of Psoriatic Arthritis in Patients with and without Prior Anti-TNF Exposure
Abstract Number: 276

Long-Term Outcome in Mixed Connective Tissue Disease
Abstract Number: 1816

Long-Term Outcome of Tacrolimus Therapy As a Maintenance Strategy in Patients with Lupus Nephritis
Abstract Number: 2046

Long-Term Outcomes in Cardiac Neonatal Lupus and Associated Risk Factors for Morbidity

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].